Clinical development of denovoSkin™
denovoSkin™ is being clinically tested for burns and reconstructive indications in children and adults. It is investigational and not yet approved.
From first-in-human to Phase III
The standard of care in burn, plastic and reconstructive surgery, autografting, is limited by donor site shortage and can leave permanent scars. The denovoSkin™ programme compares the graft with autografting to establish safety and efficacy.
Sources: cutiss.swiss, UZH News, January 2026
Safety, first in human
Completed with a five-year follow-up, with 10 paediatric patients at the University Children’s Hospital Zurich.
Three randomised, controlled trials
Adult and adolescent burns, paediatric burns, and reconstructive surgery at all ages, with denovoSkin™ compared to autografting on every patient (intra-patient control).
Ongoing, randomised and controlled
Started in spring 2025 for severe burns in adults and adolescents, in burn centres across eight EU countries and Switzerland, to confirm safety and efficacy.
Individual access
denovoSkin™ is also accessible under compassionate use.
For surgeons and burn centres
If your centre is interested in the clinical programme or in compassionate use, the CUTISS clinical team can share the current trial sites and criteria.
Contact the clinical team
For patients and families
Recovering from a severe burn or preparing for reconstructive surgery raises many questions. This page explains what denovoSkin™ is. It is not medical advice.
What you should know
denovoSkin™ is a personalised skin graft grown from a small biopsy of the patient’s own healthy skin.
It is still being studied in clinical trials and is not yet approved, so it is not available as a standard treatment.
Participation in a trial is decided by the treating burn centre and depends on its criteria. Please speak with your surgical team first.
Ask a question